Vidaza Unione Europea - croato - EMA (European Medicines Agency)

vidaza

bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Azacitidine Celgene Unione Europea - croato - EMA (European Medicines Agency)

azacitidine celgene

celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Azacitidine Mylan Unione Europea - croato - EMA (European Medicines Agency)

azacitidine mylan

mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Sunitinib Pharmascience 12,5 mg tvrde kapsule Croazia - croato - HALMED (Agencija za lijekove i medicinske proizvode)

sunitinib pharmascience 12,5 mg tvrde kapsule

pharmascience international limited, lampousas, 1, nicosia, cipar - sunitinibklorid - kapsula, tvrda - urbroj: jedna kapsula sadrži 12,5 mg sunitiniba u obliku sunitinibklorida

Sunitinib Pharmascience 25 mg tvrde kapsule Croazia - croato - HALMED (Agencija za lijekove i medicinske proizvode)

sunitinib pharmascience 25 mg tvrde kapsule

pharmascience international limited, lampousas, 1, nicosia, cipar - sunitinibklorid - kapsula, tvrda - urbroj: jedna kapsula sadrži 25 mg sunitiniba u obliku sunitinibklorida

Sunitinib Pharmascience 37,5 mg tvrde kapsule Croazia - croato - HALMED (Agencija za lijekove i medicinske proizvode)

sunitinib pharmascience 37,5 mg tvrde kapsule

pharmascience international limited, lampousas, 1, nicosia, cipar - sunitinibklorid - kapsula, tvrda - urbroj: jedna kapsula sadrži 37,5 mg sunitiniba u obliku sunitinibklorida

Sunitinib Pharmascience 50 mg tvrde kapsule Croazia - croato - HALMED (Agencija za lijekove i medicinske proizvode)

sunitinib pharmascience 50 mg tvrde kapsule

pharmascience international limited, lampousas, 1, nicosia, cipar - sunitinibklorid - kapsula, tvrda - urbroj: jedna kapsula sadrži 50 mg sunitiniba u obliku sunitinibklorida